Table 2.
Change in best-corrected visual acuity, central choroidal thickness, and central subfield macular thickness in patient population after the initial switch to intravitreal faricimab
Parameters | Pre-treatment with IVF | Post-treatment with IVF | Difference (post − pre) | P-value |
---|---|---|---|---|
LogMAR BCVA (SD)a | 0.34 (0.37) | 0.36 (0.40) | 0.016 (0.13) | 0.29 |
CST, µm (SD)a | 242 (72) | 242 (82) | 0.13 (65) | 0.99 |
CCT, µm (SD)a | 189 (98) | 179 (97) | − 10 (18)a | < 0.0001 |
aPaired t-test